IRIS UniCatt

Richeldi, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.537
EU - Europa 4.177
AS - Asia 2.263
SA - Sud America 342
AF - Africa 91
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 9
Totale 11.453
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.441
IT - Italia 1.078
SG - Singapore 976
SE - Svezia 889
CN - Cina 549
DE - Germania 404
PL - Polonia 390
IE - Irlanda 311
BR - Brasile 290
FR - Francia 240
GB - Regno Unito 219
ID - Indonesia 215
RU - Federazione Russa 157
FI - Finlandia 138
IN - India 130
AT - Austria 70
HK - Hong Kong 66
CA - Canada 65
BE - Belgio 57
NL - Olanda 50
UA - Ucraina 41
IR - Iran 39
JP - Giappone 37
VN - Vietnam 35
AU - Australia 28
KR - Corea 28
CH - Svizzera 27
TR - Turchia 25
SA - Arabia Saudita 24
CI - Costa d'Avorio 22
CZ - Repubblica Ceca 20
PK - Pakistan 19
AR - Argentina 18
MX - Messico 18
EG - Egitto 16
CO - Colombia 14
PH - Filippine 14
TW - Taiwan 13
LT - Lituania 12
MA - Marocco 12
MY - Malesia 12
PT - Portogallo 12
RO - Romania 11
TN - Tunisia 11
AE - Emirati Arabi Uniti 10
BD - Bangladesh 9
ES - Italia 9
EU - Europa 8
IL - Israele 8
ZA - Sudafrica 8
GR - Grecia 7
IQ - Iraq 7
KZ - Kazakistan 7
JO - Giordania 6
NZ - Nuova Zelanda 6
BZ - Belize 5
DK - Danimarca 5
EE - Estonia 5
LV - Lettonia 5
NG - Nigeria 5
NP - Nepal 5
PE - Perù 5
SD - Sudan 5
UZ - Uzbekistan 5
EC - Ecuador 4
LK - Sri Lanka 4
MD - Moldavia 4
NO - Norvegia 4
TH - Thailandia 4
UY - Uruguay 4
HR - Croazia 3
KE - Kenya 3
KG - Kirghizistan 3
PA - Panama 3
PY - Paraguay 3
AM - Armenia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
BT - Bhutan 2
CM - Camerun 2
CR - Costa Rica 2
ET - Etiopia 2
HU - Ungheria 2
MG - Madagascar 2
MO - Macao, regione amministrativa speciale della Cina 2
MT - Malta 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CL - Cile 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
KW - Kuwait 1
ME - Montenegro 1
MK - Macedonia 1
MM - Myanmar 1
Totale 11.449
Salva come PNG Salva come JPEG
Città #
Chandler 675
Singapore 582
Ashburn 396
Warsaw 380
Fairfield 332
Dublin 310
Rome 242
Jakarta 212
Milan 211
Wilmington 190
Beijing 187
Woodbridge 157
Princeton 148
San Mateo 136
Houston 133
Seattle 133
The Dalles 127
Boston 123
Moscow 109
New York 109
Helsinki 108
Munich 108
Ann Arbor 105
Chicago 97
Cambridge 95
Nuremberg 72
North Bergen 61
Los Angeles 50
London 48
Brussels 47
Boardman 44
Hong Kong 43
Frankfurt am Main 42
Jacksonville 41
Marseille 38
Bremen 37
Düsseldorf 31
Vienna 31
Augusta 30
Dearborn 28
Redwood City 28
Dong Ket 27
Hyderabad 26
Kish 25
Nanjing 25
Washington 25
Cattolica 23
Abidjan 22
Pune 21
Trieste 21
San Diego 20
Casalecchio di Reno 19
Council Bluffs 19
Norwalk 19
Lappeenranta 18
Shanghai 18
São Paulo 18
Kunming 17
Portsmouth 16
Toronto 16
Amsterdam 15
Brno 15
Columbus 15
Lauterbourg 15
Tokyo 15
Paris 14
Santa Clara 14
Falkenstein 13
Zurich 13
Buenos Aires 12
Dammam 12
Guangzhou 12
Hangzhou 12
Nanchang 12
Andover 11
Busto Arsizio 11
Chiswick 11
Oggiono 11
Ottawa 11
Rio de Janeiro 11
Turin 11
Belo Horizonte 10
Bern 10
Bologna 10
Changsha 10
Leawood 10
Sydney 10
Boydton 9
Brasília 9
Central 9
Fremont 9
Millbury 9
Mumbai 9
Naples 9
Springfield 9
Taipei 9
Cairo 8
Des Moines 8
Monterrey 8
Monza 8
Totale 6.910
Salva come PNG Salva come JPEG
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 449
Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit. 377
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 171
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage 168
Subclinical interstitial lung abnormalities: Lumping and splitting revisited 163
Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey 156
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): Insights from the INPULSIS® trials 154
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis 145
Idiopathic Pulmonary Fibrosis: State of the Art for 2023 140
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 140
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 133
Assessment of neurological manifestations in hospitalized patients with COVID-19 131
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 115
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 114
A real-time integrated framework to support clinical decision making for covid-19 patients 114
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 111
Reply to Moodley and to Ravaglia et al 110
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 109
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 106
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: Pooled data from six clinical trials 96
Digital lung auscultation: Will early diagnosis of fibrotic interstitial lung disease become a reality? 95
Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis 95
Sarilumab use in severe SARS-CoV-2 pneumonia 92
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 91
The characterisation of interstitial lung disease multidisciplinary team meetings: A global study 91
Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue 88
Residual respiratory impairment after COVID-19 pneumonia 85
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 84
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial 83
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline 82
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 81
Vaccines and Myocardial Injury in Patients Hospitalized for COVID-19 Infection: the CardioCOVID-Gemelli Study 80
Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: Relationships with disease progression and pulmonary function trends 80
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 79
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society 79
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 77
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis 75
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 74
Acute Respiratory Distress Syndrome and Lung Fibrosis Complicating Surgery in a Patient with Crohn's Disease 73
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study 71
COVID-19 and interstitial lung disease: Keep them separate 71
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper 70
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry 70
Residual respiratory impairment after COVID-19 pneumonia 69
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia 69
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 68
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 68
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 67
Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: Preliminary results 67
Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study 67
Treatment strategies for asthma: Reshaping the concept of asthma management 67
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: Preliminary findings 67
Severe asthma: One disease and multiple definitions 67
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 65
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial) 64
New frontiers in ultrasonography of the mediastinum: Pediatric EBUS-TBNA 64
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 64
Malnutrition in COVID-19 survivors: prevalence and risk factors 63
Malnutrition in COVID-19 survivors: prevalence and risk factors 63
Idiopathic pulmonary fibrosis 63
Current and Future Idiopathic Pulmonary Fibrosis Therapy 63
Antibody-based therapies for idiopathic pulmonary fibrosis 63
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't 62
Challenges in the diagnosis of idiopathic pulmonary fibrosis: the importance of a multidisciplinary approach 61
Statin therapy and lung disorders 61
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations 61
Progressive Fibrosing Interstitial Lung Disease A Proposed Integrated Algorithm for Management 60
Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective 60
Accuracy and Predictors of Success of EUS-B-FNA in the Diagnosis of Pulmonary Malignant Lesions: A Prospective Multicenter Italian Study 60
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis 59
Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy 57
Determinants and Evolution of Obstructive Sleep Apnea Syndrome After Myocardial Infarction 57
Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study 57
Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis 56
The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: Surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory 55
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities 54
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities 54
COVID-19 atypical Parsonage-Turner syndrome: a case report 53
Antibody-based therapies for idiopathic pulmonary fibrosis 53
Reply to: Huang and Wei, Kang et al., and Ehteshami-Afshar and Raj 53
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF) 52
Advances with pharmacotherapy for the treatment of interstitial lung disease 52
Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement 52
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants 51
Theatre as research and catalyst for health promotion 51
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study 51
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial 51
Restless legs syndrome: A new comorbidity in idiopathic pulmonary fibrosis 51
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data 51
Post-COVID lung fibrosis: The tsunami that will follow the earthquake 51
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial 50
Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis 50
Current Diagnosis and Management of Hypersensitivity Pneumonitis 50
Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal? 50
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey 50
Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease 50
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis 49
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis 49
Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions 48
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis 48
Totale 8.356
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.595
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.595
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020260 0 0 0 0 0 0 0 0 0 0 194 66
2020/20211.456 52 112 117 99 137 116 256 199 88 133 72 75
2021/20221.506 141 75 29 155 56 48 30 237 61 68 339 267
2022/20232.924 315 302 274 430 270 355 136 179 310 147 132 74
2023/20242.037 69 436 91 100 102 211 136 75 90 149 234 344
2024/20253.062 121 97 362 207 325 211 226 234 759 416 104 0
Totale 11.775